Metal-Induced Folding of Metallothionein
A R T I C L E S
2
0-22
and funga.
These single-domain proteins have been shown
structure because for the first time we report a property of MT
that directly relates to the presence of the two domains. We
report the rate constant for the first As3 bound is 65% faster
for the two-domain protein than for the single domain fragments
and that there is an almost linear correlation between the binding
rates for the incoming metal and the number of available sites.
Hence, a two-domain protein binds metals dramatically faster
than the individual domains. Assuming a constant koff, we can
for the first time, contrast that the k1ꢀR (for the first metal bound)
is 6.8× greater than k6ꢀR (for the last metal bound).
to contain a highly conserved central segment that correlate to
the domain center of mammalian MT and may be considered
the core upon which many MTs have evolved.
Metal homeostasis, which is necessary for survival of all
organisms, requires buffering of metals via both metalation
reactions that store the metals and metal exchange reactions
into apoproteins. One of MT’s suggested functions involves
metal homeostasis; MT appears to play a role in zinc homeo-
stasis as the Zn2 buffering capacity of MT may control cellular
+
2
3
+
2
4
Zn availability. This buffering capacity of MT is based on
MT’s ability to undergo metalation, demetalation and metal
exchange reactions. The steady state metalation/demetalation
equilibria for MTs are well-known for a large number of
Experimental Methods
Materials and Methods. Experimental procedures have previ-
1
ously been published; please refer to Ngu et al. for further details.
7
,15,25-28
metals
and numerous metal exchange studies with MT
Recombinant human metallothionein (hMT) was expressed in
BL21(DE3) Escherichia coli cells that were transformed using a
pP-1 plasmid which contains an N-terminal S-tag (MKETAAAKFE
6
,13,29,30
have been documented.
While metal exchange in MT
has been studied extensively, the detailed mechanism of
metalation showing all intermediate species has been hard to
determine, mainly because of a lack of probes that can
differentiate the binding of more than one metal in dilute
solutions. Recent studies have shown that mass spectrometry
is able to discriminate between different intermediates and
further, quantify the relative concentrations of all species
3
8,39
RQHMDSPDLG TLVPRGS) as previously described.
The
S-tag was removed using a Thrombin CleanCleave Kit (Sigma).
The RhMT, ꢀhMT, and ꢀRhMT proteins used in this study were
based on the 43-residue, 40-residue, and 74-residue sequences,
respectively. The sequence for RhMT is GSMGKAAAAC CSC-
CPMSCAK CAQGCVCKGA SEKCSCCKKA AAA; for ꢀhMT
is GSMGKAAAAC SCATGGSCTC TGSCKCKECK CNSCK-
KAAAA, and for ꢀRhMT is GSMGKAAAAC SCATGGSCTC
TGSCKCKECKCNSCKKAAAACCSCCPMSCAKCAQGCVCKG
ASEKCSCCKK AAAA. There are 11, 9, and 20 cysteine residues
present in RhMT, ꢀhMT and ꢀRhMT, respectively, and no disulfide
bonds. The protein was further purified and demetalated by elution
through a Sephadex G25 column with a 20 mM ammonium formate
buffer at pH 2.7 (Fisher). Elution was monitored by UV-visible
absorption spectroscopy at the characteristic metal-free (apo) MT
wavelengths of 300 to 200 nm. Fractions that contained metal-free
MT were collected and purity was checked using ESI-MS. Previous
reports have suggested or shown the existence of apoprotein in
3
1-35
36
present
for kinetic experiments.
Shaw and Petering have reported that Cd and Zn2+
metalation is largely complete at pH 7 and room temperature
within the 4 ms dead-time of the stopped-flow UV-visible
spectometer used. On the other hand arsenic-metalation of
MT occurs on a time-scale of minutes and is observable by
2+
3
7
1
mass spectrometry making it an ideal reaction to study to obtain
a detailed understanding of the metal-induced folding reactions
3+
of metallothionein. We report the first detailed As -metalation
study on the two-domain ꢀR human metallothionein showing
all intermediate As-species with correlations to the native
individual single domain fragments. The data analysis reported
here provides insight into the evolution of the two-domain
2
4,40-48
ViVo
making the study of apoprotein relevant as a starting
3+
point in exploring the metalation reactions of As . The apo-RhMT
protein concentrations were determined from the extinction coef-
ficients of 40,000 Lmol cm at 220 nm, the Cd
concentrations were determined from the extinction coefficient of
36,000 Lmol cm at 250 nm, and the Cd
was determined from the extinction coefficient of 115,000
Lmol cm at 250 nm. The protein concentration for the kinetic
ESI-MS experiment using the thermostatted-mixing tee was 19.5
µM of apo-ꢀRMT and concentrations for the timed-resolved ESI-
MS experiments were 18 µM for apo-ꢀRMT, 23 µM for apo-RMT
and a 30 µM for apo-ꢀMT. Oxidation is a significant problem with
solutions of MT in these experiments and the apo-proteins were
maintained in their reduced state by carefully deoxygenating the
-
1
-1
3
-ꢀhΜΤ protein
(
20) Claderone, V.; Dolderer, B.; Hartmann, H.-J.; Echner, H.; Luchinat,
-1
1
C.; Bianco, C. D.; Mangani, S.; Weser, U. Proc. Natl. Acad. Sci. U.S.A.
7
-ꢀR protein concentration
2
005, 102, 51–56.
(
21) Munger, K.; Germann, U. A.; Lerch, K. EMBO J. 1985, 4, 2665–
-1
-1
2
668.
(
22) Munger, K.; Lerch, K. Biochemistry 1985, 24, 6751–6756.
23) Nemer, M.; Wilkinson, D. G.; Travaglini, E. C.; Sternberg, E. J.; Butt,
T. R. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 4992–4994.
(
(
(
(
24) Krezel, A.; Maret, W. J. Biol. Inorg. Chem. 2008, 13, 401–409.
25) Rigby Duncan, K. E.; Stillman, M. J. FEBS J. 2007, 274, 2253–2261.
26) Chan, J.; Huang, Z.; Watt, I.; Kille, P.; Stillman, M. J. Can. J. Chem.
2
007, 85, 898–912.
(
(
(
(
(
(
(
(
(
(
(
27) Shaw, C. F.; He, L.; Munoz, A.; Savas, M. M.; Chi, S.; Fink, C. L.;
Gan, T.; Petering, D. H. J. Biol. Inorg. Chem. 1997, 2, 65–73.
28) Palumaa, P.; Eriste, K.; Kruusel, K.; Kangur, L.; Joernvall, H.; Sillard,
R. Cell. Mol. Biol. 2003, 49, 763–768.
(38) Merrifield, M. E.; Huang, Z.; Kille, P.; Stillman, M. J. J. Inorg.
Biochem. 2002, 88, 153–172.
(39) Chan, J.; Huang, Z.; Merrifield, M. E.; Salgado, M. T.; Stillman, M. J.
Coord. Chem. ReV. 2002, 233-234, 319–339.
29) Salgado, M. T.; Bacher, K. L.; Stillman, M. J. J. Biol. Inorg. Chem.
2
007, 12, 294–312.
30) Nettesheim, D. G.; Engeseth, H. R.; Otvos, J. D. Biochemistry 1985,
4, 6744–6751.
31) Hathout, Y.; Fabris, D.; Fenselau, C. Int. J. Mass Spectrom. 2001,
04, 1–6.
32) Yu, X.; Wojciechowski, M.; Fenselau, C. Anal. Chem. 1993, 65, 1355–
359.
33) Zaia, J.; Fabris, D.; Wei, D.; Karpel, R. L.; Fenselau, C. Protein Sci.
998, 7, 2398–2404.
34) Daneshfar, R.; Kitova, E. N.; Klassen, J. S. J. Am. Chem. Soc. 2004,
(40) Krezel, A.; Maret, W. Biochem. J. 2007, 402, 551–558.
(41) Pattanaik, A.; Shaw, C. F. I.; Petering, D. H.; Garvey, J. S.; Kraker,
A. J. J. Inorg. Biochem. 1994, 54, 91–105.
2
(42) Rigby, K. E.; Chan, J.; Mackie, J.; Stillman, M. J. Proteins: Struct.,
Funct., Bioinf. 2006, 62, 159–172.
2
(43) Rigby, K. E.; Stillman, M. J. Biochem. Biophys. Res. Commun. 2004,
325, 1271–1278.
1
(44) Hase, H.; Maret, W. Anal. Biochem. 2004, 333, 19–26.
(45) Yang, Y.; Maret, W.; Vallee, B. L. Proc. Natl. Acad. Sci. U.S.A. 2001,
98, 5556–5559.
1
1
26, 4786–4784.
(46) Shapiro, S. G.; Squibb, K. S.; Markowitz, L. A.; Cousins, R. J.
Biochem. J. 1978, 175, 833–840.
35) Shoemaker, G. K.; Kitova, E. N.; Palcic, M. M.; Klassen, J. S. J. Am.
Chem. Soc. 2007, 129, 8674–8675.
(47) Krezoski, S. K.; Villalobos, J.; Shaw, C. F. I.; Petering, D. H. Biochem.
J. 1998, 255, 483–491.
36) Wang, W.; Kitova, E. N.; Klassen, J. S. Anal. Chem. 2003, 75, 4945–
4
955.
(48) Petering, D. H.; Zhu, J.; Krezoski, S. K.; Meeusen, J.; Kiekenbush,
C.; Krull, S.; Specher, T.; Dughish, M. Exp. Biol. Med. 2006, 231,
1528–1534.
37) Ejnik, J.; Robinson, J.; Zhu, J.; Forsterling, H.; Shaw, C. F.; Petering,
D. H. J. Inorg. Biochem. 2002, 88, 144–152.
J. AM. CHEM. SOC. 9 VOL. 130, NO. 50, 2008 17017